This research investigates a novel two-drug therapy for ovarian cancer that kills cancer cells without harming healthy tissues and partially reactivates the suppressed immune system. The PhD work explores how this immune “reawakening” occurs, aiming to identify new strategies to enhance it and create more effective, resistance-proof treatments.